An official website of the United States government
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Trial Status: active
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with
Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic
Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual
Disease (MRD) negative response
Inclusion Criteria
Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World Health Organization (WHO) classification, and either relapse/refractory or MRD positive
Age: Lower age limit of ≥ 1 year; adequate organ function
Eastern Cooperative Oncology Group (ECOG)/Karnofsky Performance Status 0 or 1/70 and above at Screening (Adults age > 16) or Lansky Performance Status 70 and above (pediatrics/ adolescents age ≤16). Key
Exclusion Criteria
Treatment with any prior anti-CD7 therapy.
Patients with decompensated hemolytic anemia.
Presence of Grade 2 to 4 acute or extensive chronic GvHD requiring systemic immunosuppression (e.g. steroids). Grade 1 GvHD not requiring immunosuppression or Grade 2 skin GvHD if treated with topical therapy only are acceptable.
Additional locations may be listed on ClinicalTrials.gov for NCT06514794.
Locations matching your search criteria
United States
California
Duarte
City of Hope Comprehensive Cancer Center
Status: Active
Name Not Available
Los Angeles
Children's Hospital Los Angeles
Status: Active
Name Not Available
Missouri
Saint Louis
Siteman Cancer Center at Washington University
Status: Active
Name Not Available
Texas
Houston
M D Anderson Cancer Center
Status: Active
Name Not Available
This is a Phase 2, single-arm, multi-center, open label study in patients with R/R
T-ALL/LBL and T-ALL/LBL in remission but remaining MRD positive.
